Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Free Cash Flow: 2020-2024

Historic Free Cash Flow for Entrada Therapeutics (TRDA) over the last 5 years, with Dec 2024 value amounting to -$44.7 million.

  • Entrada Therapeutics' Free Cash Flow fell 13.00% to -$28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$129.8 million, marking a year-over-year decrease of 643.23%. This contributed to the annual value of -$44.7 million for FY2024, which is 133.32% down from last year.
  • Entrada Therapeutics' Free Cash Flow amounted to -$44.7 million in FY2024, which was down 133.32% from $134.2 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Free Cash Flow ranged from a high of $134.2 million in FY2023 and a low of -$96.7 million during FY2022.
  • Over the past 3 years, Entrada Therapeutics' median Free Cash Flow value was -$44.7 million (recorded in 2024), while the average stood at -$2.4 million.
  • Per our database at Business Quant, Entrada Therapeutics' Free Cash Flow spiked by 238.81% in 2023 and then tumbled by 133.32% in 2024.
  • Over the past 5 years, Entrada Therapeutics' Free Cash Flow (Yearly) stood at -$27.9 million in 2020, then crashed by 98.80% to -$55.4 million in 2021, then slumped by 74.37% to -$96.7 million in 2022, then skyrocketed by 238.81% to $134.2 million in 2023, then slumped by 133.32% to -$44.7 million in 2024.